Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy

Nature Communications

Volumn 6, Issue , 2015, Pages

  Karakikes, Ioannis ^a,b   Stillitano, Francesca ^a   Nonnenmacher, Mathieu ^a   Tzimas, Christos ^c   Sanoudou, Despina ^d   Termglinchan, Vittavat ^b   Kong, Chi Wing ^e   Rushing, Stephanie ^a   Hansen, Jens ^a   Ceholski, Delaine ^a   Kolokathis, Fotis ^d   Kremastinos, Dimitrios ^d   Katoulis, Alexandros ^d   Ren, Lihuan ^e   Cohen, Ninette ^a   Gho, Johannes M I H ^f   Tsiapras, Dimitrios ^g   Vink, Aryan ^f   Wu, Joseph C ^b   Asselbergs, Folkert W ^f,h,i   Li, Ronald A ^a,e   Hulot, Jean Sebastien ^a,j   Kranias, Evangelia G ^c,k   Hajjar, Roger J ^a   more..

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^d UNIVERSITY OF ATHENS   (Greece)

^e UNIVERSITY OF HONG KONG   (Hong Kong)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g ONASSIS CARDIAC SURGERY CENTER   (Greece)

^h ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

^j SORBONNE UNIVERSITÉ   (France)

^k UNIVERSITY OF CINCINNATI   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; MICRORNA; PHOSPHOLAMBAN; R14DEL PROTEIN; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; UNCLASSIFIED DRUG; CALCIUM BINDING PROTEIN; DEOXYRIBONUCLEASE;

ABNORMALITY; CALCIUM; CARDIOLOGY; CORRELATION; ENZYME ACTIVITY; GENE; MUTATION; PHENOTYPE;

ARTICLE; CALCIUM HOMEOSTASIS; CARDIOMYOPATHY; CELLULAR DISTRIBUTION; CHROMOSOME ABERRATION; CONTROLLED STUDY; ELECTROSTIMULATION; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE TRANSFER; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KARYOTYPING; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAXIMUM DIASTOLIC POTENTIAL; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PYROSEQUENCING; RNA SEQUENCE; SKIN BIOPSY; TARGETED GENE REPAIR; ADENOVIRIDAE; ADULT; CARDIAC MUSCLE CELL; CARDIOMYOPATHIES; GENE DELETION; GENETICS; INDUCED PLURIPOTENT STEM CELL; METABOLISM; PHENOTYPE;

ADENOVIRIDAE; ADULT; CALCIUM-BINDING PROTEINS; CARDIOMYOPATHIES; DEOXYRIBONUCLEASES; FEMALE; GENE TRANSFER TECHNIQUES; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MYOCYTES, CARDIAC; PHENOTYPE; SEQUENCE DELETION; TARGETED GENE REPAIR;

EID: 84928966984     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms7955     Document Type: Article

References (50)

1. Hershberger, R. E., Hedges, D. J. & Morales, A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. Nat. Rev. Cardiol. 10, 531-547 (2013).
2. Dellefave, L. & McNally, E. M. The genetics of dilated cardiomyopathy. Curr. Opin. Cardiol. 25, 198-204 (2010).
3. Schmitt, J. P. et al. Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299, 1410-1413 (2003).
4. Haghighi, K. et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J. Clin. Invest. 111, 869-876 (2003).
5. Haghighi, K. et al. A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc. Natl Acad. Sci. USA 103, 1388-1393 (2006).
6. van Spaendonck-Zwarts, K. Y. et al. Genetic analysis in 418 index patients with idiopathic dilated cardiomyopathy: overview of 10 years' experience. Eur. J. Heart Fail. 15, 628-636 (2013).
7. MacLennan, D. H. & Kranias, E. G. Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell Biol. 4, 566-577 (2003).
8. Posch, M. G. et al. Genetic deletion of arginine 14 in phospholamban causes dilated cardiomyopathy with attenuated electrocardiographic R amplitudes. Heart Rhythm 6, 480-486 (2009).
9. van der Zwaag, P. A. et al. Phospholamban R14del mutation in patients diagnosed with dilated cardiomyopathy or arrhythmogenic right ventricular cardiomyopathy: evidence supporting the concept of arrhythmogenic cardiomyopathy. Eur. J. Heart Fail. 14, 1199-1207 (2012).
10. Haghighi, K. et al. The human phospholamban Arg14-deletion mutant localizes to plasma membrane and interacts with the Na/K-ATPase. J. Mol. Cell Cardiol. 52, 773-782 (2012).
11. DeWitt, M. M., MacLeod, H. M., Soliven, B. & McNally, E. M. Phospholamban R14 deletion results in late-onset, mild, hereditary dilated cardiomyopathy. J. Am. Coll. Cardiol. 48, 1396-1398 (2006).
12. van der Zwaag, P. A. et al. Recurrent and founder mutations in the Netherlands-Phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy. Neth. Heart J. 21, 286-293 (2013).
13. Moretti, A. et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N. Engl. J. Med. 363, 1397-1409 (2010).
14. Egashira, T. et al. Disease characterization using LQTS-specific induced pluripotent stem cells. Cardiovasc. Res. 95, 419-429 (2012).
15. Lahti, A. L. et al. Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis. Model Mech. 5, 220-230 (2012).
16. Matsa, E. et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur. Heart J. 32, 952-962 (2011).
17. Itzhaki, I. et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 471, 225-229 (2011).
18. Davis, R. P. et al. Cardiomyocytes derived from pluripotent stem cells recapitulate electrophysiological characteristics of an overlap syndrome of cardiac sodium channel disease. Circulation 125, 3079-3091 (2012).
19. Yazawa, M. et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 471, 230-234 (2011).
20. Fatima, A. et al. In vitro modeling of ryanodine receptor 2 dysfunction using human induced pluripotent stem cells. Cell Physiol. Biochem. 28, 579-592 (2011).
21. Jung, C. B. et al. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia. EMBO Mol. Med. 4, 180-191 (2012).
22. Novak, A. et al. Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to beta-adrenergic stimulation. J. Cell Mol. Med. 16, 468-482 (2012).
23. Kim, C. et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature 494, 105-110 (2013).
24. Lan, F. et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 12, 101-113 (2013).
25. Lee, Y. K. et al. Modeling of Friedreich ataxia-related iron overloading cardiomyopathy using patient-specific-induced pluripotent stem cells. Pflugers Arch. 466, 1831-1844 (2014).
26. Sun, N. et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci. Transl. Med. 4, 130ra147 (2012).
27. Hajjar, R. J. & Hulot, J. S. Modeling CVD in human pluripotent cells by genome editing. J. Am. Coll. Cardiol. 64, 460-462 (2014).
28. Warren, L. et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 7, 618-630 (2010).
29. Bock, C. et al. Reference maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines. Cell 144, 439-452 (2011).
30. Karakikes, I. et al. Small molecule-mediated directed differentiation of human embryonic stem cells toward ventricular cardiomyocytes. Stem Cells Transl. Med. 3, 18-31 (2014).
31. MacLennan, D. H. & Kranias, E. G. Phospholamban: a crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell Biol. 4, 566-577 (2003).
32. Lister, R. et al. Hotspots of aberrant epigenomic reprogramming in human induced pluripotent stem cells. Nature 471, 68-73 (2011).
33. Miller, J. C. et al. A TALE nuclease architecture for efficient genome editing. Nat. Biotechnol. 29, 143-148 (2011).
34. Guschin, D. Y. et al. A rapid and general assay for monitoring endogenous gene modification. Methods Mol. Biol. 649, 247-256 (2010).
35. Veres, A. et al. Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. Cell Stem Cell 15, 27-30 (2014).
36. Suzuki, K. et al. Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones. Cell Stem Cell 15, 31-36 (2014).
37. Smith, C. et al. Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. Cell Stem Cell 15, 12-13 (2014).
38. Germanguz, I. et al. Molecular characterization and functional properties of cardiomyocytes derived from human inducible pluripotent stem cells. J. Cell Mol. Med. 15, 38-51 (2011).
39. Rapti, K. et al. Effectiveness of gene delivery systems for pluripotent and differentiated cells. Mol. Ther. 2, 14067; doi:10.1038/mtm.2014.67 (2015).
40. Haghighi, K. et al. A human phospholamban promoter polymorphism in dilated cardiomyopathy alters transcriptional regulation by glucocorticoids. Hum. Mutat. 29, 640-647 (2008).
41. Wang, Y. et al. Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing. J. Am. Coll. Cardiol. 64, 451-459 (2014).
42. Wang, G. et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat. Med. 20, 616-623 (2014).
43. Jiang, J., Wakimoto, H., Seidman, J. G. & Seidman, C. E. Allele-specific silencing of mutant Myh6 transcripts in mice suppresses hypertrophic cardiomyopathy. Science 342, 111-114 (2013).
44. Mearini, G. et al. Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice. Nat. Commun. 5, 5515 (2014).
45. Ludwig, T. E. et al. Feeder-independent culture of human embryonic stem cells. Nat. Methods 3, 637-646 (2006).
46. Karakikes, I. et al. Small molecule-mediated directed differentiation of human embryonic stem cells toward ventricular cardiomyocytes. Stem Cells Transl. Med. 3, 18-31 (2013).
47. Hockemeyer, D. et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat. Biotechnol. 29, 731-734 (2011).
48. Wang, Z. et al. Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther. 10, 2105-2111 (2003).
49. Grimm, D., Kay, M. A. & Kleinschmidt, J. A. Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6. Mol. Ther. 7, 839-850 (2003).
50. Du, G., Yonekubo, J., Zeng, Y., Osisami, M. & Frohman, M. A. Design of expression vectors for RNA interference based on miRNAs and RNA splicing. FEBS J. 273, 5421-5427 (2006).